

IPR and Innovation

1. [Pharma price control has stunted innovation, study finds](#) – The Times of India
2. [Compulsory license application may prove to be test for Modi govt](#) – Mint
3. [The curious case of Indian innovation](#) – The Financial Express

Access to Healthcare

1. [Price control ineffective in improving access to drugs: Report](#) – The Economic Times
2. [Medical bills driving millions to debt](#) – Deccan Herald

Medical & Regulatory

1. [IPA wants Centre to bring in clarity on Rule 96 & Schedule G drugs under Rule 97](#) – Pharmabiz.com
2. [Bitter pill for pharma firms over clinical trials](#) – Bloomberg TV
3. [IPC identifies 30 new AMCs under PvPI bringing total number of AMCs to 180](#) – Pharmabiz.com
4. [CDSCO-NIB survey of NSQ drugs to test 43000 collected samples in 10 govt labs](#) – Pharmabiz.com
5. [US FDA bans Emcure Pharmaceuticals' Maharashtra plant over manufacturing issues](#) – The Economic Times

Others

1. [MSDE teams up with health ministry to double skilled workforce to 74 lakh by 2022](#) – Pharmabiz.com
2. [Resisting antibiotic resistance](#) – Mint

IPR and Innovation

1. [Pharma price control has stunted innovation, study finds](#) – The Times of India
Consumers may be happy at a cut in medicine bills but the government's price control measures have forced many brands out of the "unviable" pharmaceutical market, resulting in a drastic slowdown in new launches in the last five years. From an average of four new drugs being launched in any specific category in 2011, the number has dropped to a mere one in 2014-15, implying a 75% decline in new launches, according to estimates by IMS Health — a leading healthcare market research agency Consumers may be happy at a cut in medicine bills but the government's price control measures have forced many brands out of the "unviable" pharmaceutical market, resulting in a drastic slowdown in new launches in the last five years.
2. [Compulsory license application may prove to be test for Modi govt](#) – Mint
The reason for the industry's keen anticipation of the decision is because the govt had assured protection of IP rights to multinational pharmaceutical firms operating in India. After a gap of about two years, the filing of a compulsory license (CL) application against a patented drug owned by a multinational company has got the Indian pharmaceutical industry holding its breath in anticipation.

3. [The curious case of Indian innovation](#) – The Financial Express
India's slide as a global innovation hub continues. Not only is India expected to perform poorly on this year's World Bank sponsored Global Innovation Index, slated to be released later this month, the country drew a blank on the 2015 Bloomberg Innovation Index, an annual ranking of the world's 50 most innovative countries. All of the BRICS nations, except India, and even countries like Malta and Tunisia, were featured on the list.

Access to Healthcare

1. [Price control ineffective in improving access to drugs: Report](#) – The Economic Times
Price control as a strategy to improve access to medicines in India is neither effective nor sustainable, a report by global information and technology services company IMS Health has said. The report suggests a combination of healthcare financing and non-financing measures such as promoting joint and bulk procurement mechanisms and investment in capacity building be adopted by the government to address the issues of access and affordability.
2. [Medical bills driving millions to debt](#) – Deccan Herald
The latest National Sample Survey Office (NSSO) figures reveal that the overwhelming majority of Indians – around 80 per cent – do not have any medical insurance cover. Around 86 per cent of India's rural population and 82 per cent of its urban masses are not covered by any kind of medical insurance. This is worrying as most Indians are dependent on private medical facilities for treatment. Nearly 80 per cent of outpatient and 60 per cent of inpatient care is in private hospitals. Since private healthcare is very expensive, a large proportion of people's earnings in India go towards medical treatment.

Medical & Regulatory

1. [IPA wants Centre to bring in clarity on Rule 96 & Schedule G drugs under Rule 97](#) – Pharmabiz.com
Keen on getting clarity on certain provisions pertaining to the Drugs and Cosmetics (D&C) Act and Rules, the Indian Pharmaceutical Association (IPA) recently made a detailed representation to Central Drugs Standard Control Organisation (CDSCO) officials in Delhi seeking their intervention. Interestingly, CDSCO had called upon the meeting with key stakeholders in mid-June to deliberate over key issues and suggestions relating to the draft amendments to the D&C Act and Rules, of which IPA was also an integral part.
2. [Bitter pill for pharma firms over clinical trials](#) – Bloomberg TV
Pharma and consumer products companies are bracing for some tough times ahead as the government is looking to amend the Drugs and Cosmetic Rules 1945 to tighten rules and increase penalties for erring officials.
3. [IPC identifies 30 new AMCs under PvPI bringing total number of AMCs to 180](#) – Pharmabiz.com
The Indian Pharmacopoeia Commission (IPC) recently added 30 new adverse drug reaction monitoring centres (AMCs) under the Pharmacovigilance Programme of India (PvPI) bringing the total number of AMCs under its ambit to 180. Interestingly IPC, which acts as the national coordinating centre (NCC) for the PvPI have selected two AMCs from northeastern state of Arunachal Pradesh for the first time.
4. [CDSCO-NIB survey of NSQ drugs to test 43000 collected samples in 10 govt labs](#) – Pharmabiz.com
Following completion of sampling of spurious and not-of-standard quality (NSQ) drugs as a part of a nationwide survey, the Central Drugs Standard Control Organisation (CDSCO) in association with

National Institute of Biologicals (NIB) is in the process of testing for the first time all drug samples for assessing the proportion of drugs which are NSQ.

5. [US FDA bans Emcure Pharmaceuticals' Maharashtra plant over manufacturing issues](#) – The Economic Times
The US Food and Drug Administration has banned drug imports from an India manufacturing unit of Emcure Pharmaceuticals Ltd over violations of standard manufacturing practices, the latest in a series of Indian firms to face such action.

Others

1. [MSDE teams up with health ministry to double skilled workforce to 74 lakh by 2022](#) – Pharmabiz.com
Ministry of skill development and entrepreneurship (MSDE) has teamed up with ministry of health and family welfare to address the industry's need for skilled human resources. Healthcare sector employs around 36 lakh employees and is slated to employ more than 74 lakh by 2022 to meet the market demand. It would comprise short term skills training to a minimum of one lakh people, in the public and private sector.
2. [Resisting antibiotic resistance](#) – Mint
Multi-drug resistant bacteria (MDR) in humans and animals have become a pandemic. Antibiotic resistance occurs when a few bacteria mutate in a given population that enables them to survive antibiotics. Scientists and public health officials have been constantly raising alarm about it but to no avail.